The EPO has granted a patent to Domain Therapeutics’ Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.
Tag Archive for: Domain Therapeutics
The EPO has granted a patent to Domain Therapeutics’ Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.